Trial Profile

A global multicentre, open-label Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APG 3288 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

27 Jan 2026 New trial record
14 Jan 2026 According to an Ascentage Pharma media release, the company expected the BTK Protein Degrader APG-3288 global Phase I PK, safety, tolerability, efficacy data, including U.S. and China in 2026.
06 Jan 2026 According to Ascentage Pharma media release, APG-3288 has received IND clearance from the USFDA, the company will now conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com